Alchemia banks on 2010

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.

Equity increased from around $87 million to $102 million.

The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Content from other channels on our network

Researchers achieve brine concentration using waste heat or sunlight

ARENA backs Orica on renewable hydrogen production

Sparc Hydrogen receives $2.75m commercialisation grant

Green approach to increase wastewater recycling in regional towns

US company to receive $4.9m from ARENA for solar installation robot trial

Returnable deli containers on trial in two NZ supermarkets

Olivo and Brunetti Oro: cool partnership for fine food

Maxum Foods appoints its first CEO

Suntory Oceania’s $3bn beverage business launched in Qld

Heat and Control showcases sustainable food processing solutions

Wage theft: law changes, compliance and prevention in health care

Deepfakes mimicking health professionals pose real risk

Diagnostic reference levels for mammography now a step closer

Renewal fee rebate for parental and other leave now in effect

SA reaches state-first allied health enterprise agreement